Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Items 401–500 of 892
Wiederhold, N. P., & Patterson, T. F. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000203 · Cited by 23
Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals
Sun, J., Nie, P., Herdewijn, P. A., & Li, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116051 · Cited by 16
Bernhardt, H., Knoke, M., & Bernhardt, J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02036.x · Cited by 18
Bailly, S., Leroy, O., Azoulay, É., Montravers, P., Constantin, J., Dupont, H., Guillemot, D., Lortholary, O., Mira, J. P., Pérrigault, P.-F., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2016.12.016 · Cited by 17
Choi, H., Kim, J. H., Seong, H., Lee, W. J., Jeong, W., Ahn, J. Y., Jeong, S. J., Ku, N. S., Yeom, J., Kim, Y. K., et al. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.03.039 · Cited by 15
Tashiro, S., Osa, S., Igarashi, Y., Watabe, Y., Liu, X., Enoki, Y., Taguchi, K., Mayumi, T., Miyazaki, Y., Takesue, Y., et al. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.06.008 · Cited by 19
Żyrek, D., Wajda, A., Czechowicz, P., Nowicka, J., Jaśkiewicz, M., Neubauer, D., & Kamysz, W. (2021) · Antibiotics · doi:10.3390/antibiotics10081001 · Cited by 19
“causing VVC clinically refractory to first-line therapy often show sensitivity to fluconazole under laboratory conditions [57,58].”
BackgroundLiposomal amphotericin B—the future
Hoenigl, M., Lewis, R. E., van de Veerdonk, F. L., Verweij, P. E., & Cornely, O. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac353 · Cited by 20
Antifúngicos para uso sistémico
Ruíz-Camps, I., & Cuenca‐Estrella, M. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2009.04.001 · Cited by 41
Echinocandin Antifungal Drug Resistance in Candida Species: A Cause for Concern?
Sanguinetti, M., Posteraro, P., & Posteraro, B. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0131-2 · Cited by 17
Tratamiento de las infecciones fúngicas en pacientes con neoplasias hematológicas
Mensa, J., de la Cámara, R., Carreras, E., Estrella, M. C., Rodríguez, J. Á. G., Gobernado, M., Picazo, J., Aguado, J. M., & Sanz, M. Á. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.01.008 · Cited by 19
Drugs Active against Fungi, Pneumocystis, and Microsporidia
Rex, J. H., & Stevens, D. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00039-4 · Cited by 18
Bal, A. M., & McGill, M. (2018) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2018.203 · Cited by 17
Invasive fungal infections in cancer patients
Anaissie, E. J., Grazziutti, M., & Nucci, M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00020-7 · Cited by 19
Defining standards of CARE for invasive fungal diseases in the ICU
Cuenca‐Estrella, M., Kett, D. H., & Wauters, J. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz038 · Cited by 18
Self-citationManagement of osteoarticular fungal infections in the setting of immunodeficiency
Papachristou, S., Iosifidis, Ε., Sipsas, N. V., Gamaletsou, M. N., Walsh, T. J., & Roilides, E. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1748499 · Cited by 16
“and invasive candidiasis, as well as superior activity in clinical trials for treatment of candidemia [79,80].”
BackgroundSelf-citationAraujo, J. M., de Almeida, J. N., Magri, M. M. C., Costa, S. F., & Guimarães, T. (2024) · Journal of Fungi · doi:10.3390/jof10040268 · Cited by 18
Bal, A. M., Pana, Z. D., Carlesse, F. A. D. M. C., Marek, A., Seidel, D., Mehler, K., Butzer, S., Sprute, R., Stemler, J., Ludwig-Bettin, D., et al. (2025) · Mycoses · doi:10.1111/myc.70041 · Cited by 16
Almyroudis, N. G., & Segal, B. H. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.141 · Cited by 16
Pappas, P. G., Kauffman, C. A., Andes, D. R., Benjamin, D. K., Calandra, T., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598961 · Cited by 26
“El fluconazol sigue siendo la terapia estándar para pacientes identificados con candidemia, basándose en los abundantes datos obtenidos de ensayos clı́nicos bien diseñados [27, 28, 53, 79].”
BackgroundSelf-citationvan der Geest, P. J., Rijnders, B. J. A., Vonk, A. G., & Groeneveld, A. B. J. (2015) · Mycoses · doi:10.1111/myc.12450 · Cited by 17
Candidemia in the patient with malignancy
Alves, J., Palma, P., Azevedo, D., & Rello, J. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1508290 · Cited by 19
“This approach had similar outcomes when compared to maintenance treatment with echinocandins [53,55,62].”
ResultFrequency and Clinical Features of Candida Bloodstream Infection Originating in the Urinary Tract
Elbaz, M., Chikly, A., Meilik, R., & Ben‐Ami, R. (2022) · Journal of Fungi · doi:10.3390/jof8020123 · Cited by 17
“Echinocandins have been shown to be superior to fluconazole for the treatment of invasive candidiasis [25,30].”
BackgroundManagement of candidaemia and invasive candidiasis in critically ill patients
Chahoud, J., Kanafani, Z. A., & Kanj, S. S. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.04.008 · Cited by 23
“…followed fluconazole (400 mg/day) after 3–7 days Mora-Duarte et al., 2002 [45] (n = 224) Caspofungin (70 mg Day 1, then 50 mg/da AmB (0.6–1 mg/kg/day) Reboli et al., 2007 [44] (n = 245) Anidulafungin (200 mg Day 1, then 100 m fluconazole (800 mg Day 1, then 400 mg/ Kuse et al., 2007 [46] (n =…”
InfluentialKaragöz, E., Uğan, R. A., Düzgun, E., Çadırcı, E., Keleş, S., Uyanik, M. H., Yavan, İ., & Turhan, V. (2016) · Current Eye Research · doi:10.3109/02713683.2016.1170857 · Cited by 15
“Completed clinical studies have demonstrated that anidulafungin is useful as a first-line agent for treating a range of serious fungal infections, including candidemia, invasive candidiasis, and azole-refractory mucosal candidiasis.(20,32,34,35) In general, the results suggest that anidulafungin will probably be more…”
BackgroundCretella, D. A., Barber, K. E., King, S. T., & Stover, K. R. (2016) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000383 · Cited by 16
“What role these discrepant results play in differences in therapeutic outcomes with echinocandins and fluconazole remains to be determined (Reboli et al., 2007; Andes et al., 2012; Pappas et al., 2016).”
BackgroundRex, J. H., & Stevens, D. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00040-0 · Cited by 20
Anidulafungin, a New Echinocandin: Effectiveness and Tolerability
Menichetti, F. (2009) · Drugs · doi:10.2165/11315570-000000000-00000 · Cited by 16
“In a recently published multicentre, doubleblind, randomized clinical trial, intravenous anidulafungin, at a loading dose of 200mg followed by 100mg/day, was compared with intravenous fluconazole, at loading dose of 800mg on day 1 followed by 400mg/day, in patients with candidaemia and/or invasive candidiasis.([19]) A…”
BackgroundMarr, K. A. (2008) · Clinical Infectious Diseases · doi:10.1086/528715 · Cited by 16
Treatment of invasive candidiasis: between guidelines and daily clinical practice
Tagliaferri, E., & Menichetti, F. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1029916 · Cited by 14
“Fluconazole was considered an option as first-line treatment of candidemia in stable patients by the 2009 IDSA guidelines (AI), based on the evidence that less critical patients with IC/C treated with fluconazole or anidulafungin had a similar mortality [24].”
BackgroundClinical Aspects of Invasive Candidiasis in Critically Ill Patients
Pennisi, M. A., & Antonelli, M. M. (2009) · Drugs · doi:10.2165/11315590-000000000-00000 · Cited by 16
“Clinical efficacy of different echinocandins in the treatment of candidaemia and invasive candidiasis has been demonstrated in comparative and non-comparative trials.([36,38,39]) Both caspofungin and micafungin showed similar efficacy to amphotericin B in non-inferiority studies,([36,38]) and in one study, micafungin…”
BackgroundResultWang, Y., McGuire, T., Hollingworth, S., Dong, Y., & van Driel, M. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.10.016 · Cited by 15
Kanji, J. N., Laverdière, M., Rotstein, C., Walsh, T. J., Shah, P. S., & Haider, S. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.745073 · Cited by 14
Self-citationNoninferior Antibiotics: When Is “Not Bad” “Good Enough”?
DiNubile, M. J. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw110 · Cited by 15
“Such a 2-step paradigm in which superiority is only tested after noninferiority has been concluded does not increase the probability of a Type 1 error [22].”
BackgroundVerma, A., Auzinger, G. M., Kantecki, M., Campling, J., Spurden, D., Percival, F., & Heaton, N. D. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw241 · Cited by 14
“The global response at the end of anidulafungin treatment in a comparative trial versus fluconazole [3] was also similar at 75.”
BackgroundResultOpportunistic and Systemic Fungi
Kosmidis, C., & Denning, D. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00189-1 · Cited by 19
Ryan, P., Motherway, C., Powell, J., Elsaka, A., Sheikh, A., Jahangir, A., O’Connell, N. H., & Dunne, C. P. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.01.017 · Cited by 15
Honoré, P. M., Bassetti, M., Cornely, O. A., Dupont, H., Fortün, J., Kollef, M. H., Pappas, P. G., Pullman, J. R., Vázquez, J. A., Bielicka, I., et al. (2024) · Critical Care · doi:10.1186/s13054-024-05152-2 · Cited by 19
“[16] There was high heterogeneity in the data and the confidence intervals for differences between treatment arms were wide.”
BackgroundSelf-citationKrishnan-Natesan, S., Manavathu, E. K., Cutright, J. L., & Chandrasekar, P. H. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.02.020 · Cited by 13
Grau, S., Salavert, M., Laderas, J. C. P., Vargas, M., Barrueta, J. A., & Mir, N. (2013) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2013.05.004 · Cited by 15
Chew, K. L., Octavia, S., Jureen, R., Lin, R. T. P., & Teo, J. W. P. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13516 · Cited by 13
“Initial therapy with echinocandins offers mortality benefit over fluconazole, and are recommended as first line therapy (Reboli et al. 2007; Pappas et al. 2016).”
BackgroundKarthaus, M., Rüping, M. J. G. T., Cornely, O. A., Steinbach, A., Groll, A. H., Lass‐Flörl, C., Ostermann, H., Ruhnke, M., & Vehreschild, J. J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01988.x · Cited by 14
Komorowski, A. S., Bai, A. D., Cvetkovic, A., Mourad, O., Lo, C. K. L., Li, X. X., Mokashi, V., Findlater, A. R., Duncan, D. B., Fuller, C. J., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.003 · Cited by 15
New and emerging options for management of invasive fungal diseases in paediatric patients
Groll, A. H., Körholz, K. F., Holterhus, M., & Lehrnbecher, T. (2023) · Mycoses · doi:10.1111/myc.13654 · Cited by 15
Girmenia, C., Finolezzi, E., Federico, V., Santopietro, M., & Perrone, S. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.013 · Cited by 17
Anidulafungin Treatment of Candidal Central Nervous System Infection in a Murine Model
Kang, C., Rouse, M. S., Mandrekar, J. N., Steckelberg, J. M., & Patel, R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00646-09 · Cited by 13
“Echinocandins have excellent clinical activity in the treatment of invasive candidiasis (10, 15).”
BackgroundChandrasekar, P. H., Sirohi, B., Seibel, N. L., Hsu, J. W., Azie, N. E., Wu, C., & Ruhnke, M. (2018) · Mycoses · doi:10.1111/myc.12748 · Cited by 13
Hill, D. M., Guido, A., Sultan-Ali, I., Arif, F., & Velamuri, S. R. (2020) · Burns · doi:10.1016/j.burns.2020.10.028 · Cited by 13
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
Wiederhold, N. P., Cota, & Frei, C. R. (2009) · Infection and Drug Resistance · doi:10.2147/idr.s3864 · Cited by 19
“…by these species have been reported to respond to echinocandin therapy, the clinical signifi cance of this reduced potency is unclear as clinical trials have not been powered to assess effi cacy against these species (Mora-Duarte et al 2002; Kuse et al 2007; Pappas et al 2007; Reboli et al 2007).”
Vehreschild, J. J., Rüping, M. J. G. T., Steinbach, A., & Cornely, O. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903405639 · Cited by 13
“However, a recent study showed superior efficacy of anidulafungin against IC [96].”
Lewis, J. S., & Ellis, M. W. (2008) · Current Opinion in Internal Medicine · doi:10.1097/qco.0b013e3282f1beb8 · Cited by 14
Candidemia in ICU Patients: What Are the Real Game-Changers for Survival?
de Almeida, B. L., Agnelli, C., Guimarães, T., Sukiennik, T., Lima, P. R. P., Salles, M. J. C., Breda, G. L., Queiroz‐Telles, F., Mendes, A. V. A., Camargo, L. F. A., et al. (2025) · Journal of Fungi · doi:10.3390/jof11020152 · Cited by 20
Treatment of candidemia in adult patients without neutropenia - an inconvenient truth
Póvoa, P. M. S. R., & Gonçalves-Pereira, J. (2011) · Critical Care · doi:10.1186/cc9414 · Cited by 14
“A recent study from Reboli and colleagues [ 6 ] suggests that anidulafungin might be superior to fl uconazole as primary therapy for candidemia in non-neutropenic patients (75.6% success with anidul afungin compared to 60.2% with fl uconazole).”
ResultInfluentialGhanem‐Zoubi, N., Zorbavel, D., Khoury, J., Geffen, Y., Qasum, M., Predescu, S., & Paul, M. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3389-1 · Cited by 13
Cuenca‐Estrella, M. (2010) · Revista española de quimioterapia. Suplemento · Cited by 12
Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients
Ferrada, M. A., Quartin, A. A., Kett, D. H., & Morris, M. I. (2013) · BMC Anesthesiology · doi:10.1186/1471-2253-13-37 · Cited by 12
“Perhaps more importantly, controlled trials have not evaluated initial therapy; enrollment criteria permitted up to 48 hours of antifungal therapy before initiation of study drug [16,18,19].”
BackgroundResultSelf-citationRecomendaciones para el manejo de la candidemia en neonatos en América Latina
Santolaya, M. E., Matute, T. A., Telles, F. D. Q., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.06.002 · Cited by 18
Anidulafungin in the treatment of patients with invasive candidiasis
Kett, D. H., & Cubillos, G. F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70008-6 · Cited by 12
“In a post hoc analysis of patients who were either critically ill or had evidence of acute organ dysfunction at study entry, patients receiving anidulafungin (ANID) compared with fluconazole (FLU) had numerically greater, albeit statistically non-significant, global response rates [10].”
BackgroundResultSelf-citationShoham, S., Groll, A. H., Petraitis, V., & Walsh, T. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00156-8 · Cited by 16
Self-citationKapralos, I., Mainas, E., Apostolopoulou, O., Siopi, M., Neroutsos, E., Apostolidi, S., Dimοpoulos, G., Sambatakou, H., Valsami, G. N., Meletiadis, J., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14457 · Cited by 13
“parapsilosis (0%) suggest higher and lower efficacy, respectively, than the global response found in the randomized trial for those infections (56% and 64%, respectively).(20,21) As mentioned above, the PK performance of ICU patients enrolled in our study is similar to that previously reported, so the proposed PK/PD t…”
MethodResultQin, J., Yang, H., Shan, Z., Jiang, L., & Zhang, Q. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001434 · Cited by 14
Tissue Distribution of Anidulafungin in Neonatal Rats
Ripp, S. L., Aram, J. A., Bowman, C., Chmielewski, G., Conte, U., Cross, D. M., Gao, H., Lewis, E. M., Lin, J., Liu, P., et al. (2012) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20347 · Cited by 12
Anidulafungin: A Novel Echinocandin for Candida Infections
de la Torre, P., Meyer, D. K., & Reboli, A. C. (2008) · Future Microbiology · doi:10.2217/17460913.3.6.593 · Cited by 12
Self-citationAnidulafungin versus Fluconazole for Invasive Candidiasis
Kumar, A. (2008) · Yearbook of Critical Care Medicine · doi:10.1016/s0734-3299(08)70531-8 · Cited by 12
Perkhofer, S., & Lass‐Flörl, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903160658 · Cited by 13
“The Emax of anidulafungin was superior to that of fluconazole and in the neutropenic animal model anidulafungin was more efficacious than fluconazole [49,50].”
BackgroundMicafungin for the prophylaxis and treatment ofCandidainfections
Fritz, J. M., Brielmaier, B. D., & Dubberke, E. R. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.2.153 · Cited by 15
“Increased serum creatinine, hypokalemia, rigors, and infusion-related reactions were significantly more common in patients administered liposomal amphotericin B. However, both study drugs were administered as 1-h infusions for blinding purposes [ 60 ].”
BackgroundResultInfluentialKuti, E. L., & Kuti, J. L. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.518143 · Cited by 14
“4% for anidulafungin and fluconazole, respectively [71].”
Bennett, J. E. (2008) · Clinical Infectious Diseases · doi:10.1086/528692 · Cited by 12
Rezafungin: A Review in Invasive Candidiasis
Fung, S. S.-P., & Shirley, M. (2025) · Drugs · doi:10.1007/s40265-024-02134-0 · Cited by 17
“Among these, anidulafungin has shown superior efficacy over fluconazole (the former first-line therapy) in treating invasive candidiasis [8].”
Craver, C., Tarallo, M., Roberts, C. S., Blanchette, C. M., & Ernst, F. R. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.001 · Cited by 12
Genomic epidemiology of human candidaemia isolates in a tertiary hospital
Chew, K. L., Achik, R., Osman, N. H., Octavia, S., & Teo, J. W. P. (2023) · Microbial Genomics · doi:10.1099/mgen.0.001047 · Cited by 17
“High mortality rates are reported even with antifungal therapy [1].”
Walsh, T. J. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae257 · Cited by 14
“Global clinical response, which has been used as a reliable end point in clinical trials for candidemia, may also be valid in studies of rare IFDs [87, 88].”
BackgroundSelf-citationEspinel‐Ingroff, A., & Cantón, E. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70002-7 · Cited by 13
“metapsilosis (3) ≥ 1 (14-23) 32 (19) ≥ 1 (4-30) C.”
Infección fúngica invasiva en los pacientes ingresados en las áreas de críticos
Garnacho‐Montero, J., Díaz‐Martín, A., de Piappon, M. R. P., & García-Cabrera, E. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.02.011 · Cited by 24
Pea, F. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.836058 · Cited by 11
Predictors of choice of initial antifungal treatment in intraabdominal candidiasis
Lagunes, L., Borgatta, B., Martín-Gómez, M. T., Rey-Perez, A., Antonelli, M. M., Righi, E., Merelli, M., Brugnaro, P., Dimopoulos, G., Garnacho‐Montero, J., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.06.005 · Cited by 11
van der Geest, P. J., Hunfeld, N., Ladage, S. E., & Groeneveld, A. B. J. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1825-3 · Cited by 12
“The overall response rates in this study are comparable to those found in other performed studies [11, 32].”
ResultOstrosky-Zeichner, L. L., Paetznick, V. L., Rodriguez, J., Chen, E., & Sheehan, D. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00955-08 · Cited by 12
“The largest randomized trial of AFG for invasive candidiasis systematically excluded patients with infection by C. krusei since the comparator was FLU ( 18 ).”
BackgroundSystemic Candidiasis: Candidemia and Deep-Organ Infections
Clancy, C. J., & Nguyen, M. H. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch27 · Cited by 15
Anidulafungin: a drug evaluation of a new echinocandin
Joseph, J., Kim, R., & Reboli, A. C. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.13.2339 · Cited by 11
Self-citationDuration of systemic antifungal therapy for patients with invasive fungal diseases: A reassessment
Gressens, S. B., Rouzaud, C., Lamoth, F., Calandra, T., Lanternier, F., & Lortholary, O. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101347 · Cited by 10
New antifungal agents for the treatment of candidaemia
Muñóz, P., Guinea, J., Rojas, L., & Bouza, E. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.007 · Cited by 14
“fluconazole for the treatment of invasive candidiasis was assessed in a randomized double-blind non-inferiority trial [34].”
BackgroundMethodAdvances in systemic antifungal therapy
Stevens, D. A. (2012) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2011.09.018 · Cited by 12
Hampered by historical paradigms – echinocandins and the treatment of Candida endocarditis
Gardiner, B. J., Slavin, M. A., Korman, T. M., & Stuart, R. L. (2013) · Mycoses · doi:10.1111/myc.12154 · Cited by 10
Dreyfuss, D., Ricard, J.-D., & Gaudry, S. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.187.6.661 · Cited by 9
Epidemiology and Outcomes of Candidemia in a Referral Center in Tehran.
Salehi, M., Ghomi, Z., Mirshahi, R., Manshadi, S. A. D., & Rezahosseini, O. (2019) · PubMed Central · doi:10.22088/cjim.10.1.73 · Cited by 11
“One of the few articles in this field compared the efficacy of anidulafungin and fluconazole on 345 patients with candidemia (34).”
BackgroundLausch, K. R., Søgaard, M., Rosenvinge, F. S., Johansen, H. K., Boysen, T., Røder, B. L., Mortensen, K. L., Nielsen, L. B., Lemming, L. E., Olesen, B. R. S., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s176384 · Cited by 11
Santos, C. A. Q., Rhee, Y., Czapka, M. T., Kazi, A. S., & Proia, L. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030865 · Cited by 12
Sandaradura, I., Wojciechowski, J., Marriott, D. J. E., Day, R. O., STOCKER, S. L., & Reuter, S. E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02019-20 · Cited by 10
Anidulafungin: an evidence-based review of its use in invasive fungal infections
Vazquez, J. (2007) · Core evidence · doi:10.2147/ce.s7433 · Cited by 10
“…some flushing, nausea, and dyspnea were reported; however, infusion-related reactions quickly subside and can be greatly reduced with slower infusion rates. specific monitoring parameters are routinely recommended in patients receiving anidulafungin (Krause et al. 2004ab; Reboli et al. 2007).”
Actividad antifúngica in vitro de la micafungina
Quindós, G., Eraso, E., Carrillo‐Muñoz, A. J., Cantón, E., & Pemán, J. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70006-3 · Cited by 9
“Candida albicans AND 4073 0’03-2 0’03 [22,39,50,52,55,71]”
BackgroundInfluentialEchinocandins in invasive candidiasis
Simon, J., Sun, H., Leong, H. N., Barez, M. Y., Huang, P., Talwar, D., Wang, J.-H., Mansor, M. M., Wahjuprajitno, B., Patel, A. K., et al. (2013) · Mycoses · doi:10.1111/myc.12085 · Cited by 12
Prise en charge des infections systémiques à Candida spp.
Taieb, F., Mechai, F., Lefort, A., Lanternier, F., Bougnoux, M., & Lortholary, O. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2010.08.019 · Cited by 15
Masterton, R. G., Casamayor, M., Musingarimi, P., van Engen, A., Zinck, R., Odufowora-Sita, O., & Odeyemi, I. A. O. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.839948 · Cited by 11
Nett, J. E., & Andes, D. R. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch22 · Cited by 11
Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients
Escamilla, J. E., January, S. E., & Guillamet, R. V. (2023) · Pathogens · doi:10.3390/pathogens12050694 · Cited by 10
Invasive Candida infections in solid organ transplant recipients between 2008 and 2020
Meyer, L., Frossard, J., Schreiber, P. W., Manuel, O., Lamoth, F., Khanna, N., Boggian, K., Walti, L. N., Garzoni, C., van Delden, C., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.07.2480 · Cited by 11
Update: invasive Pilzinfektionen: Diagnose und Therapie in der operativen Intensivmedizin
Lichtenstern, C., Swoboda, S., Hirschburger, M., Domann, E., Hoppe‐Tichy, T., Winkler, M., Lass‐Flörl, C., & Weigand, M. A. (2010) · Der Anaesthesist · Cited by 9
Chastain, D. B., White, B. P., Tu, P. J., Chan, S., Jackson, B., Kubbs, K. A., Bandali, A., McDougal, S., Henao‐Martínez, A. F., & Cluck, D. B. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231175201 · Cited by 11
Soriano, À., Honoré, P. M., Cornely, O. A., Chayakulkeeree, M., Bassetti, M., Haihui, H., Dupont, H., Kim, Y. K., Kollef, M. H., Kullberg, B. J., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae363 · Cited by 10
“The safety and tolerability of rezafungin were comparable to caspofungin in this analysis and were consistent with previously published findings from ReSTORE [17] and for first-generation echinocandins [18, 20].”
Self-citation
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.